Press releases

Karo Healthcare strengthens its portfolio of skin health brands in Northern Europe

Following the closing of KKR’s acquisition of Karo Healthcare (“Karo”) on 27 August, Karo today confirms that the agreement to acquire a portfolio of skin health brands, including ACO, has been transferred to Karo. The pending transaction was previously announced by a KKR-affiliated vehicle and Perrigo Company plc (“Perrigo”) on 14 July, 2025, and the terms remain unchanged with the transaction expected to close in Q1 2026. Perrigo’s Dermacosmetics branded business, which generated more than EUR 120 million in net sales in 2024 across the Nordics, the Netherlands, and Poland, includes trusted, science-backed skincare brands and has a strong strategic fit with Karo’s business.

Karo Group publishes the 2024 Sustainability Report

Today, on 15 April 2025, Karo Group* is publishing its 2024 Sustainability Report on the company’s website, www.karohealthcare.com. For further information, please contact: Christoffer Lorenzen, CEO, +46 735 017 620,…

Karo Healthcare announces KKR as new owner, following successful strategic transformation into pan-European consumer healthcare player

Karo Healthcare (“Karo”) will change owner following the announcement that EQT has agreed to sell Karo to funds managed by KKR, a leading global investment firm. The transaction marks a…

Karo Healthcare appoints Egil Molsted Madsen as CFO

We are pleased to announce that Egil Molsted Madsen will assume the role of CFO at Karo starting on 3 October 2024. Egil, a Danish national, brings a wealth of…

Karo Healthcare appoints Egil Mølsted Madsen as CFO

We are pleased to announce that Egil Mølsted Madsen will assume the role of CFO at Karo starting on 3 October 2024. Egil, a Danish national, brings a wealth of…

Karo Group publishes the 2023 Sustainability Report

Today, on 15 April 2024, Karo Group* is publishing its 2023 Sustainability Report on the company’s website, www.karohealthcare.com. For further information, please contact: Christoffer Lorenzen, CEO, +46 735 017 620,…

Karo Healthcare expands its presence in Italy with the acquisition of the rights to Proctosedyl® from Bayer

Karo Healthcare AB (‘Karo’) announces the acquisition of the rights to the OTC brand Proctosedyl from Bayer. The transaction transfers global dossier ownership to the OTC pharmaceutical Proctosedyl, and exclusive…

Karo Healthcare completes the acquisition of the rights to the Global OTC brand Lamisil® from Haleon

Karo Healthcare (‘Karo’) has today completed the previously announced acquisition of the rights to the Global OTC brand Lamisil® from Haleon UK Holdings Ltd. (‘Haleon’) for a total consideration of…

Karo Healthcare acquires the Global OTC brand Lamisil® from Haleon

Karo Healthcare (‘Karo’) announces the acquisition of the rights to the Global OTC brand Lamisil® from Haleon UK Holdings Ltd. (‘Haleon’) for a total consideration of GBP 235m (EUR 274m)…

Babak Peyami Joins Karo’s Corporate Management Team as new Head of Digital Commerce

Karo Healthcare announces changes to its Corporate Management Team. Robin List transitions to an advisory role and Babak Peyami is promoted to drive Karo’s digital commerce activities. Babak joined Karo…